The US Food and Drug Administration announced today, Monday June 25, the approval of the country’s first marijuana-based prescription medication.
The drug is called Epidiolex and is a plant-derived oral solution of cannabidiol (CBD)—a chemical component of marijuana that does not cause intoxication or a euphoric “high.”
The FDA approved it for use in patients aged two and older who suffer from rare and severe forms of epilepsies known as Lennox-Gastaut syndrome and Dravet syndrome, which can develop early in childhood. Epidiolex’s approval also marks the first time the FDA has approved a drug to treat Dravet syndrome.
With the historic approval, the US Drug Enforcement Administration is expected to reclassify CBD in the coming weeks, potentially opening the doors to other marijuana-derived medications.
See the original article at Ars Technica